BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the Independent Data Monitoring Committee (IDMC) for its pivotal trial of CO-101 in metastatic pancreatic cancer, LEAP (Low hENT1 and Adenocarcinoma of the Pancreas), has informed the Company that approximately 65 percent of the patients enrolled in LEAP have been classified as hENT1-low. This analysis is based on patients enrolled in the study through late October 2011, representing over two-thirds of the planned 360 patients expected to be enrolled in the study. The hENT1-low patients are the target population for CO-101, the Company’s lipid-conjugated gemcitabine. LEAP is an international, randomized, controlled 360-patient, pivotal trial designed to demonstrate that CO-101 improves overall survival versus gemcitabine in hENT1-low metastatic pancreatic cancer patients. The Company expects to complete enrollment in LEAP at the end of the first quarter 2012.
